Literature DB >> 19883692

A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells.

Eiji Konishi1, Yuko Tabuchi, Atsushi Yamanaka.   

Abstract

A simple alternative to the dengue antibody-dependent enhancement (ADE) assay was established. The new assay method utilizes cells attached to microplate wells, thereby eliminating cumbersome procedures typical of the conventional ADE assay that utilizes suspension cells. Semi-adherent K562 cells bearing the Fc-gamma receptor (Fc gammaR) were cultured on poly-L-lysine-coated plates. The procedure consisted of (i) preparation of a virus-antibody-cell mixture in wells, (ii) cultivation at 37 degrees C for 24 h and (iii) fixation and immunostaining to count infected cells. Using monoclonal antibodies against dengue type 2 virus, the new system correlated with three conventional systems. Additionally, K562 cells were employed in a neutralization test. For this purpose, the virus-antibody mixture was incubated at 37 degrees C for 2 h prior to the addition of cells. As expected, K562 cells provided lower neutralizing antibody titers than did a conventional neutralization test using Vero cells, which do not have Fc gammaR, in monoclonals showing both neutralizing and enhancing activities. Since antibodies are present in polyclonal form in circulation, neutralization tests using K562 cells are considered to reveal a more accurate in vivo status than those using Vero cells. Human sera, positive for dengue virus antibodies, showed neutralizing and enhancing activities in a dose-dependent manner. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883692     DOI: 10.1016/j.jviromet.2009.10.026

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  16 in total

1.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

3.  Issues related to recent dengue vaccine development.

Authors:  Eiji Konishi
Journal:  Trop Med Health       Date:  2011-08-06

4.  Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.

Authors:  Yi-Chin Fan; Jo-Mei Chen; Hsien-Chung Chiu; Yi-Ying Chen; Jen-Wei Lin; Chen-Chang Shih; Chih-Ming Chen; Chao-Chin Chang; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

5.  Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells.

Authors:  Meng Ling Moi; Chang-Kweng Lim; Kaw Bing Chua; Tomohiko Takasaki; Ichiro Kurane
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

6.  Dengue transmission model by means of viremic adult immuno-competent mouse.

Authors:  Lucky Ronald Runtuwene; Eiji Konishi; Atsushi Yamanaka; Yoshihiro Makino; Yutaka Suzuki; Tomohiko Takasaki; Ichiro Kurane; Takashi Kobayashi; Yuki Eshita
Journal:  Parasit Vectors       Date:  2014-03-31       Impact factor: 3.876

Review 7.  Human antibody response to dengue virus: implications for dengue vaccine design.

Authors:  Meng Ling Moi; Tomohiko Takasaki; Ichiro Kurane
Journal:  Trop Med Health       Date:  2016-03-14

8.  Antibody-dependent enhancement representing in vitro infective progeny virus titer correlates with the viremia level in dengue patients.

Authors:  Atsushi Yamanaka; Hisham Ahmed Imad; Weerapong Phumratanaprapin; Juthamas Phadungsombat; Eiji Konishi; Tatsuo Shioda
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

9.  A novel reporter system for neutralizing and enhancing antibody assay against dengue virus.

Authors:  Ke-Yu Song; Hui Zhao; Zhen-You Jiang; Xiao-Feng Li; Yong-Qiang Deng; Tao Jiang; Shun-Ya Zhu; Pei-Yong Shi; Bo Zhang; Fu-Chun Zhang; E-De Qin; Cheng-Feng Qin
Journal:  BMC Microbiol       Date:  2014-02-18       Impact factor: 3.605

10.  Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.

Authors:  Panjaporn Chaichana; Tamaki Okabayashi; Orapim Puiprom; Mikiko Sasayama; Tadahiro Sasaki; Akifumi Yamashita; Pongrama Ramasoota; Takeshi Kurosu; Kazuyoshi Ikuta
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.